A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Purpose Cisplatin (CDDP) and etoposide (VP16) are considered major standard cytotoxic drugs for small cell lung cancer (SCLC). The present systematic review had as its objective the evaluation of their role, as components of chemotherapy regimens, on survival.Methods Published randomised clinical trials (from 1980 to 1998) were selected comparing, in SCLC patients, chemotherapy regimens, given as first-line therapy. One arm (the experimental arm) had to include CDDP and/or VP16, while another had to omit the same drug(s). Trials quality was assessed by two published scores (Chalmers and European Lung Cancer Working Party (ELCWP)). For each individual trial, the hazard ratio (HR) of the survival distributions was estimated on the basis of reported statistics or, if not available, by extracting, from the survival graphical representations, the data required to construct the difference between expected and observed numbers of events as calculated in the log-rank statistic. A combined hazard ratio was obtained by the Peto method (a value < 1 meaning a benefit for CDDP and/or VP16).Results Thirty-six trials eligible for our systematic review were identified, classified into four groups (I-IV): group I, 1 trial testing a CDDP-based regimen (without VP16) against another arm not including either CDDP or VP16; group II, 17 trials testing a VP16-based regimen (without CDDP) against a regimen without VP16 and CDDP; group III, nine trials comparing a regimen including CDDP and VP16 with a regimen using neither drug; and, finally, group IV, nine trials comparing a regimen based on both drugs with a regimen based on VP16 only. Overall, Chalmers and ELCWP scores correlated well (r(S) = 0.76, P < 0. 001) and had respective median scores of 50.3 and 63.7%. The number of eligible patients did not have a significant impact on the scores as well as the trials group, the trial positivity (a positive trial defined as showing itself a statistically significant survival benefit for the experimental regimen), overall or in categories, and the year of publication. Combined hazard ratios with 95% confidence intervals were: 0.70 (0.41-1.21) for group I, 0.72 (0.67-0.78) for II, 0.57 (0.51-0.64) for III, and 0.74 (0.66-0.83) for IV, showing a survival benefit in favour of regimens including etoposide alone or in combination with cisplatin, justifying with high significance levels the use of each of these drugs. Overall survival benefits could also be shown for regimens including CDDP (HR = 0.61; confidence interval (CI), 0.57-0.66), as well as for those including VP16 (HR = 0. 65; CI, 0.61-0.69). Robustness of these results has to be confirmed with appropriate randomised trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802 · cited 4×
“The most accurate method consisted of calculating the estimated HR and its standard error using two of the following parameters: the HR point estimate, the log-rank statistic or its P value, the O−E statistic (difference between numbers of observed and expected events) or its variance [8].”
MethodInfluentialBeta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
A method for assessing the quality of a randomized control trial
Chalmers, T. C., Smith, H., Blackburn, B., Silverman, B., Schroeder, B., Reitman, D., & Ambroz, A. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90056-8 · Cited by 1,349
Meta-analysis of the literature or of individual patient data: is there a difference?
Stewart, L. A., & Parmar, M. K. B. (1993) · The Lancet · doi:10.1016/0140-6736(93)93004-k · Cited by 769
Roth, B. J., Johnson, D. H., Einhorn, L. H., Schacter, L. P., Cherng, N. C., Cohen, H. J., Crawford, J., Randolph, J. A., Goodlow, J. L., & Broun, G. O. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.282 · Cited by 556
Fukuoka, M., Furuse, K., Saijo, N., Nishiwaki, Y., Ikegami, H., Tamura, T., Shimoyama, M., & Suemasu, K. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.12.855 · Cited by 456
Skarlos, D. V., Samantas, E., Kosmidis, P., Fountzilas, G., Angelidou, M., Palamidas, P. H., Mylonakis, N., Provata, A., Papadakis, E., Klouvas, G., et al. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058931 · Cited by 274
Pignon, J., & Stewart, L. A. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960601)77:11<2413::aid-cncr34>3.3.co;2-4 · Cited by 247
Marino, P., Preatoni, A., & Cantoni, A. (1995) · Cancer · doi:10.1002/1097-0142(19950815)76:4<593::aid-cncr2820760409>3.0.co;2-n · Cited by 239
EVANS, W. K., FELD, R., MURRAY, N., WILLAN, A., OSOBA, D., SHEPHERD, F. A., CLARK, D. A., LEVITT, M., MacDONALD, A., WILSON, K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-4-451 · Cited by 223
Research works printed but not linked: 1
- Luce, 1998, Revue critique des études randomisées évaluant le rôle de la radiothérapie adjuvante à la chimiothérapie dans le traitement du cancer bronchique à petites cellules au stade limité, Rev. Mal. Resp., 15, 633
Cited by
van Meerbeeck, J. P., Fennell, D. A., & De Ruysscher, D. K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,237
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Dingemans, A.-M. C., Früh, M., Ardizzoni, A., Besse, B., Faivre-Finn, C., Hendriks, L. E., Lantuejoul, S., Peters, S., Reguart, N., Rudin, C. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.207 · Cited by 626
“For decades, a platinum plus etoposide has been the preferred first-line treatment for extensive-stage SCLC, with a median OS of 9-10 months, PFS of 5-6 months and 1-year OS of w35% [I, A].(26) A meta-analysis of individual patient data showed no difference in OS between cisplatin and carboplatin.”
BackgroundFrüh, M., De Ruysscher, D., Popat, S., Crinò, L., Peters, S., & Felip, E. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt178 · Cited by 613
“Another meta-analysis of 36 trials reported an OS benefit in favour of etoposide alone or in combination with cisplatin compared with regimens that did not contain one of the two drugs [26].”
BackgroundGuidelines on the radical management of patients with lung cancer
Lim, E., Baldwin, D., Beckles, M., Duffy, J., Entwisle, J., Faivre-Finn, C., Kerr, K., Macfie, A., McGuigan, J., Padley, S., et al. (2010) · Thorax · doi:10.1136/thx.2010.145938 · Cited by 539
Sundstrøm, S., Bremnes, R. M., Kaasa, S., Aasebø, U., Hatlevoll, R., Dahle, R., Boye, N., Wang, M., Vigander, T., Vilsvik, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.111 · Cited by 499
Metadata
- Authors
- Mascaux, C., Paesmans, M., Berghmans, T., Branle, F., Lafitte, J. J., Lemaı̂tre, F., Meert, A. P., Vermylen, P., & Sculier, J. P.
- Affiliations
- Institut Jules Bordet (BE)
- Centre Hospitalier Universitaire de Lille (FR)
- Venue
- Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2000-10
- Volume
- 30
- Issue
- 1
- Pages
- 23-36
- ISSN
- 0169-5002 (ISSN-L)
- OpenAlex
- W2108113897
- Cited by
- 270
- References
- 55
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 17 · 2023: 12 · 2022: 8 · 2021: 11 · 2020: 5 · 2019: 4 · 2018: 6 · 2017: 9 · 2016: 7 · 2015: 8 · 2014: 9 · 2013: 19 · 2012: 13
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Lung Cancer (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- ORBi UMONS (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- small cell lung cancer, etoposide, cisplatin, first-line chemotherapy, survival, hazard ratio, trial quality assessment, combination chemotherapy, randomized controlled trials, meta-analysis of trials
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Phytogenic, Cisplatin, Etoposide, Humans, Lung Neoplasms, Prognosis, Survival Analysis, Randomized Controlled Trials as Topic, Carcinoma, Small Cell
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. https://app.cochat.ai/papers/10.1016/s0169-5002(00)00127-6
- The paper
- Mascaux, C., Paesmans, M., Berghmans, T., Branle, F., Lafitte, J. J., Lemaı̂tre, F., Meert, A. P., Vermylen, P., & Sculier, J. P. (2000). A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. https://doi.org/10.1016/s0169-5002(00)00127-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.